Bryant Furlow

Bryant Furlow is medical journalist working at the crossroads of research, clinical practice, and public policy. His work has appeared The Lancet, New Scientist, and Oncology Nurse Advisor.

Most Recent Articles by Bryant Furlow

CD19 CAR T-Cell Therapies: "Expect an Evolution"

CD19 CAR T-Cell Therapies: "Expect an Evolution"

By

"CD19 CAR therapy has paved the way for a new field of medicine based on the genetic instruction of T-cell responses," according to Dr Michel Sadelin.

Selinexor Trials Move Nuclear Suppressor Protein-Export Inhibition Closer to the Clinic for Multiple Myeloma

Selinexor Trials Move Nuclear Suppressor Protein-Export Inhibition Closer to the Clinic for Multiple Myeloma

By

XPO1 inhibition restores the ability of intranuclear tumor suppressor genes to disrupt oncoproteins; it is emerging as a promising new investigational strategy in MM.

Does Epigenetic Therapy With Panobinostat Reduce CRPC Bicalutamide Resistance?

Does Epigenetic Therapy With Panobinostat Reduce CRPC Bicalutamide Resistance?

By

Panobinostat plus bicalutamide increased radiographic progression-free survival in patients with CRPC resistant to second-line antiandrogen therapy.

EUTOS Long-Term Survival Score Outperforms Sokal in TKI-Treated CML

EUTOS Long-Term Survival Score Outperforms Sokal in TKI-Treated CML

By

EUTOS long-term survival score better predicted prognosis for those with chronic myeloid leukemia who had been treated with TKIs—especially among elderly patients.

Daratumumab Combination: New Standard of Care in Transplant-Ineligible Multiple Myeloma

Daratumumab Combination: New Standard of Care in Transplant-Ineligible Multiple Myeloma

By

The findings may support the triplet regimen as a new standard of care for these patients, according to Dr Facon.

More Articles by Bryant Furlow

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs